689299-71-6

Basic information

• Product Name: (E)-3-(4'-chloro-biphenyl-4-yl)-N-(4-piperidin-1-ylmethyl-phenyl)-acrylamide
• Synonyms: (E)-3-(4'-chloro-biphenyl-4-yl)-N-(4-piperidin-1-ylmethyl-phenyl)-acrylamide
• CAS NO: 689299-71-6
• Molecular Weight: 430.977
• Mol File: 689299-71-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (E)-3-(4'-chloro-biphenyl-4-yl)-N-(4-piperidin-1-ylmethyl-phenyl)-acrylamide(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-3-(4'-chloro-biphenyl-4-yl)-N-(4-piperidin-1-ylmethyl-phenyl)-acrylamide(689299-71-6)
• EPA Substance Registry System: (E)-3-(4'-chloro-biphenyl-4-yl)-N-(4-piperidin-1-ylmethyl-phenyl)-acrylamide(689299-71-6)

Safety Data

• Hazardous Substances Data: 689299-71-6(Hazardous Substances Data)

Upstream product

• 29608-05-7 1-(4-aminobenzyl)piperidine 
• 83281-26-9 3-(4'-chloro-biphenyl-4-yl)-acrylic acid 
• 689303-00-2 (E)-3-(4’-chloro-[1,1‘-biphenyl]-4-yl)acrylate 

Downstream Products

• 858678-06-5 2,3-dibromo-3-(4'-chloro-biphenyl-4-yl)-N-(4-piperidin-1-ylmethyl-phenyl)-propionamide 

Relevant articles and documents

Design, synthesis and evaluation of MCH receptor 1 antagonists - Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition

Abstract Despite recent success there remains a high therapeutic need for the development of drugs targeting diseases associated with the metabolic syndrome. As part of our search for safe and effective MCH-R1 antagonists for the treatment of obesity, a s

NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS

The invention relates to amide compounds of general formula (I), in which the groups and residues A, B, b, W, X, Y, Z, R1, R2 and R3 have the meanings given in claim 1. The invention further relates to medicaments comprising at least one of said amides. Said medicaments are suitable for the treatment of metabolic disorders and/or eating disorders, in particular, obesity, bulimia, anorexia, hyperphagia, and diabetes as a result of the MCH receptor antagonism.